- Home
- RYN vs ADMA Comparison
RYN vs ADMA Comparison
Compare RYN & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYN
- ADMA
- Stock Information
- Founded
- RYN 1926
- ADMA 2004
- Country
- RYN United States
- ADMA United States
- Employees
- RYN N/A
- ADMA 624
- Industry
- RYN Real Estate Investment Trusts
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RYN Real Estate
- ADMA Health Care
- Exchange
- RYN Nasdaq
- ADMA Nasdaq
- Market Cap
- RYN 4.5B
- ADMA 4.1B
- IPO Year
- RYN N/A
- ADMA N/A
- Fundamental
- Price
- RYN $26.44
- ADMA $17.40
- Analyst Decision
- RYN Hold
- ADMA Strong Buy
- Analyst Count
- RYN 3
- ADMA 4
- Target Price
- RYN $33.67
- ADMA $21.25
- AVG Volume (30 Days)
- RYN 717.1K
- ADMA 2.8M
- Earning Date
- RYN 01-29-2025
- ADMA 11-07-2024
- Dividend Yield
- RYN 11.13%
- ADMA N/A
- EPS Growth
- RYN 98.46
- ADMA N/A
- EPS
- RYN 1.07
- ADMA 0.28
- Revenue
- RYN $1,004,107,000.00
- ADMA $382,809,000.00
- Revenue This Year
- RYN N/A
- ADMA $66.84
- Revenue Next Year
- RYN N/A
- ADMA $14.72
- P/E Ratio
- RYN $24.75
- ADMA $62.07
- Revenue Growth
- RYN 20.26
- ADMA 63.39
- 52 Week Low
- RYN $26.14
- ADMA $4.16
- 52 Week High
- RYN $35.29
- ADMA $23.64
- Technical
- Relative Strength Index (RSI)
- RYN 23.23
- ADMA 36.96
- Support Level
- RYN $26.14
- ADMA $17.32
- Resistance Level
- RYN $29.01
- ADMA $18.97
- Average True Range (ATR)
- RYN 0.66
- ADMA 0.75
- MACD
- RYN -0.51
- ADMA -0.30
- Stochastic Oscillator
- RYN 5.15
- ADMA 10.32
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. The firm also owns timberland in New Zealand. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.